Externautics
Siena
About Externautics
EXTERNAUTICS is an innovative biotech company established in 2007 to exploit the unique possibilities offered by the Reverse Proteomic YOMICS® Platform toward the identification and development of novel diagnostic and therapeutic markers for Oncology applications. The past ten years have seen a tremendous increase in the use of Monoclonal Antibodies for the treatment of cancer diseases. Herceptin and Erbitux are clear examples of the present trends of the cancer clinical therapy to target and kill tumor cells on the basis of specific protein markers present on the tumors. Yet, the frequency of tumor regression is still limited to a very low percentage of the patient population submitted to treatment.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $3.9M
- Last round: Series Unknown (Jun 2008)
- Website: externautics.com
- Phone: +39 0577 1916275
Industries & Categories
Biotechnology, Oncology
Social Profiles
Canonical: https://fsome.com/organization/externautics-1303553 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.